Loading...
Loading...
XRTX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 33.2K |
| Gross Profit | -33.2K |
| Operating Expense | 983.7K |
| Operating I/L | -4,616.8K |
| Other Income/Expense | 3,633.1K |
| Interest Income | 0.0K |
| Pretax | 2,699.2K |
| Income Tax Expense | -3,682.9K |
| Net Income/Loss | 2,699.2K |
XORTX Therapeutics Inc. is a bio-pharmaceutical company specializing in the development and commercialization of therapies for progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, and diabetic nephropathy. The company's product portfolio includes XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with COVID-19 and suppress acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidate for the treatment of diabetic nephropathy.
